Y Liu1, Y Zheng, S Li, B Li, Y Zhang, Y Yuan. 1. State Key Laboratory of Oncology in South China and Department of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Abstract
AIM: To evaluate the efficacy and safety of percutaneous microwave ablation (MWA) in patients with larger hepatocellular carcinoma (HCC) tumours. MATERIALS AND METHODS: Eighty HCC patients with the maximum tumour measuring between 3 and 8 cm were treated using MWA. Of these patients, 57 had initial HCC, while 23 had recurrent HCC. Fifty-two patients had a main tumour measuring 3-5 cm, and 28 had a main tumour measuring 5-8 cm. Local tumour control, complications, long-term survival, and prognostic factors were analysed. RESULTS: Complete ablation after the initial treatment was achieved in 70 of 80 (87.5%) patients. Sixteen of the 72 (22.2%) successfully treated patients developed local recurrence. Major complications occurred in 7.5% patients. No procedure-related mortality was observed. The 1, 2, 3, and 5 year overall survival rates after the initial ablation were 81.1, 68.2, 56.5, and 34.6%, with a median survival of 56 months. Univariate analysis revealed that small tumour size (p = 0.003) and pre-ablation α-foetoprotein (AFP) level ≤400 ng/ml (p = 0.042) were favourable prognostic factors of overall survival. Multivariate analysis identified only tumour size as the independent prognosis factor (p = 0.008). CONCLUSION: Percutaneous MWA is effective and safe for treating larger HCC tumours. The local tumour control and long-term survival are acceptable.
AIM: To evaluate the efficacy and safety of percutaneous microwave ablation (MWA) in patients with larger hepatocellular carcinoma (HCC) tumours. MATERIALS AND METHODS: Eighty HCC patients with the maximum tumour measuring between 3 and 8 cm were treated using MWA. Of these patients, 57 had initial HCC, while 23 had recurrent HCC. Fifty-two patients had a main tumour measuring 3-5 cm, and 28 had a main tumour measuring 5-8 cm. Local tumour control, complications, long-term survival, and prognostic factors were analysed. RESULTS: Complete ablation after the initial treatment was achieved in 70 of 80 (87.5%) patients. Sixteen of the 72 (22.2%) successfully treated patients developed local recurrence. Major complications occurred in 7.5% patients. No procedure-related mortality was observed. The 1, 2, 3, and 5 year overall survival rates after the initial ablation were 81.1, 68.2, 56.5, and 34.6%, with a median survival of 56 months. Univariate analysis revealed that small tumour size (p = 0.003) and pre-ablation α-foetoprotein (AFP) level ≤400 ng/ml (p = 0.042) were favourable prognostic factors of overall survival. Multivariate analysis identified only tumour size as the independent prognosis factor (p = 0.008). CONCLUSION: Percutaneous MWA is effective and safe for treating larger HCC tumours. The local tumour control and long-term survival are acceptable.
Authors: Scott M Thompson; Matthew R Callstrom; Kim A Butters; Shari L Sutor; Bruce Knudsen; Joseph P Grande; Lewis R Roberts; David A Woodrum Journal: Cardiovasc Intervent Radiol Date: 2014-01-23 Impact factor: 2.740
Authors: Andrea Veltri; Carlo Gazzera; Marco Calandri; Francesco Marenco; Andrea Doriguzzi Breatta; Paolo Fonio; Giovanni Gandini Journal: Radiol Med Date: 2015-05-31 Impact factor: 3.469
Authors: P Saccomandi; E Schena; C Massaroni; Y Fong; R F Grasso; F Giurazza; B Beomonte Zobel; X Buy; J Palussiere; R L Cazzato Journal: Eur J Surg Oncol Date: 2015-09-25 Impact factor: 4.424
Authors: Thomas Josef Vogl; Jun Qian; Andreas Tran; Elsie Oppermann; Nagy N Naguib; Huedayi Korkusuz; Nour Eldin A Nour Eldin; Wolf Otto Bechstein Journal: Diagn Interv Radiol Date: 2017 Mar-Apr Impact factor: 2.630